2025 ESC/EACTS Guidelines for the management of valvular heart disease.
Fabien Praz, Michael A Borger, Jonas Lanz...
https://pubmed.ncbi.nlm.nih.gov/40878295/Actively Recruiting
Led by Fundación EPIC · Updated on 2026-10-30
100
Participants Needed
7
Research Sites
4 weeks
Total Duration
Researchers are evaluating the success of transfemoral implantation of the Hydra THV biological aortic valve prosthesis in adults with severe symptomatic aortic stenosis. This observational study aims to assess how well the device performs and the early clinical outcomes after implantation. The device is used according to its official instructions as a CE-marked transcatheter heart valve system. Participants receive the Hydra THV device through a transfemoral transcatheter aortic valve replacement TAVR procedure. The study focuses on the procedural success and device performance during and shortly after implantation. Patients with severe aortic stenosis undergoing this procedure will be followed to monitor safety and effectiveness, including short- and mid-term clinical outcomes. During the study, participants will be monitored for procedural success and safety outcomes over several time points, including 7 days, 30 days, and 12 months after implantation. Assessments include mortality, stroke, myocardial infarction, complications, conduction disturbances, need for pacemaker implantation, heart function classifications, and echocardiographic evaluations. The study will continue to follow participants for up to approximately three years to gather detailed safety and device performance data.
CONDITIONS
Spanish Prospective Registry of Hydra THV for Transcatheter Aortic Valve Implantation
R
RAUL MORENO GOMEZ, MD, PhD
F
FUNDACION EPIC
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Fundación EPIC
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Procedure day
Participants undergo transfemoral implantation of the Hydra THV biological aortic valve prosthesis.
1 visit (procedure day)
Duration - Up to 12 months or longer
Participants are monitored for safety and device performance, including mortality, stroke, heart complications, and valve function at multiple timepoints.
Visits at 7 days, 30 days, and periodic assessments up to 12 months
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Fabien Praz, Michael A Borger, Jonas Lanz...
https://pubmed.ncbi.nlm.nih.gov/40878295/Mateo Marin-Cuartas, Michal J Kawczynski, Suzanne de Waha...
https://pubmed.ncbi.nlm.nih.gov/41672766/Audrius Aidietis, Suphot Srimahachota, Maciej Dabrowski...
https://pubmed.ncbi.nlm.nih.gov/34991828/Anmol Sonawane, Praveen Chandra, John Jose...
https://pubmed.ncbi.nlm.nih.gov/41819447/Nagendra Boopathy Senguttuvan, John Jose, Anmol Sonawane...
https://pubmed.ncbi.nlm.nih.gov/41049310/Fundación EPIC
Lead Sponsor